Using wearable data to predict heart health and cardiovascular risk
Official title: Assessment and Prediction of Cardiovascular Health and Disease Risk Using Longitudinal Wearable Biometrics: a Prospective Cohort Study.
Run by University College Dublin · NCT07401550 · Data updated 2026-11-12
This will test whether continuous Fitbit data can help track and predict heart health and future cardiovascular risk in adults.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University College Dublin Academic / other |
| Locations | 1 site (Dublin, Dublin) |
| Status | Recruiting |
| Started | December 9, 2025 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | February 10, 2026 |
| Trial ID | NCT07401550 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 and older who can attend three clinic visits at Beacon Hospital in Dublin, have internet access, and own a smartphone compatible with the Fitbit app are ideal candidates.
✕Probably not a fit
People who are pregnant, have unstable medical conditions or cognitive impairments that prevent following the protocol, or who cannot wear a wrist device (for medical or skin reasons) may not benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort will provide participants with a Fitbit Charge 6 to wear continuously for six months, with device data collected via Fitabase. Clinical cardiovascular assessments and calculation of the American Heart Association Life's Essential 8 score will be performed at baseline, three months, and six months. Participants will complete weekly and monthly patient-reported outcome surveys on symptoms, sleep, mood, alcohol use, and activity. Analyses will examine whether wearable-derived biometrics, alone or combined with point-of-care measures, correlate with and predict changes in cardiovascular health and risk factors.
Why it matters
Potential benefit: If successful, wearables could offer low-burden, continuous monitoring to detect worsening cardiovascular health earlier and support more personalized prevention.
How similar studies have gone: Prior studies have shown promising links between wearable metrics (activity, heart rate, sleep) and individual cardiovascular outcomes, but applying wearables to predict composite Life's Essential 8 scores is relatively new.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 years, or older * Internet access * Possession of a smartphone compatible with the Fitbit mobile app Exclusion Criteria: * Pregnancy * Unstable medical condition * Inability to provide informed consent * Mental or cognitive impairment precluding adherence to study protocol * Smartwatch cannot be worn, (e.g., allergic reactions), or cannot be worn in accordance with manufacturer guidelines (e.g., amputation, dark tattoos at wrist)
Where it's running
-
Beacon Hospital
Dublin, Dublin, Ireland Recruiting
Study contacts
- Principal investigator: Rory Lambe — University College Dublin
- Study coordinator: Rory Lambe
- Email: rory.lambe@ucdconnect.ie
- Phone: +353 1 716 3442
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Health for Hungary: Long-term blood and health data collection to study aging and disease onset
This study tests whether routine blood tests plus advanced molecular analyses can help detect the early stages of non-communicable diseases in adults over 40.
-
Digital health platform to help prevent and manage high blood pressure, lipids, and kidney and heart disease
This trial tests a mobile digital health platform to help people with hypertension, dyslipidemia, and related conditions in New Taipei City see if the platform improves blood pressure, cholesterol, and kidney health.
-
Cardiovascular effects of gender-affirming hormones in adults
This project tests whether masculinizing or feminizing gender-affirming hormone therapy changes heart and blood vessel health in transgender adults who have been on hormones for at least 12 months.
-
TAVI and PCI vs SAVR and CABG in low- and intermediate-risk patients with severe aortic stenosis and CAD
This observational study compares TAVI plus PCI to SAVR plus CABG for patients who have both severe aortic stenosis and coronary artery disease.
-
Tailored digital support to cut sedentary time in long-term cardiac rehab
In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.
-
Resveratrol and Estrogen Receptors in Postmenopausal Women with CAD
This study tests whether taking resveratrol is safe and can change estrogen-related markers in postmenopausal women with coronary artery disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.